Postmenopausal Osteoporosis Market Synopsis:
\nPostmenopausal Osteoporosis Market Size Was Valued at USD 12.9 Billion in 2023, and is Projected to Reach USD 20.25 Billion by 2032, Growing at a CAGR of 5.60% From 2024-2032.
\nPostmenopausal osteoporosis encompasses a situation where bones become fragile after the completion of menstruation in a woman which exposes the patient to frequent bone fractures. It is a condition predisposed by hormonal change, especially following the menopause when estrogen levels are low, bone mass and density are at low ebb. Low bone mass as a result of osteoporosis among postmenopausal women is a serious health issue since it causes fractures as well as limited physical activity and decreased quality of life. In this paper, it is agreed that identification of postmenopausal osteoporosis and its timely treatment is crucial to avoid related consequences of the ailment.
\nThe postmenopausal osteoporosis market has developed rapidly over the past few years based on the growth of the osteoporosis rate in postmenopausal women. The condition is touching a growing number of women around the world as life expectancy rates continue to rise. The market is further fueled by growing global awareness about osteoporosis disease and necessity of preventive measures, new treatment instrumentalities such as bisphosphonates, monoclonal antibodies for osteoporosis, and HRT. Also, rising usage of diagnostic devices and imaging options for early diagnosis of osteoporosis has boosted the growth of this market.
\nRegionally, North America has the largest share in postmenopausal osteoporosis market mainly due to the significant increase in population with post menopausal osteoporosis and advancement in healthcare expenditures in North America. Europe also share a major proportion, this due to the increased number of elderly, and awareness that encourages early detection and treatment. The Asia-Pacific region is anticipated to show the highest CAGR throughout the forecast period due to the rise the healthcare accessibility, awareness, and a growing population of geriatric people. That said, whilst osteoporosis treatment has been receiving increasing attention in recent years, postmenopausal osteoporosis is still vastly underdiagnosed in many parts of the world, thus creating both threats and opportunities for market participants.<\/p>\n
Postmenopausal Osteoporosis Market Trend Analysis:
\nDigital Health Technologies Transforming Osteoporosis Management<\/p>\n
The postmenopausal osteoporosis market has been witnessed to shift from traditional practices to adopting digital health technologies, the use of which enshrine novel techniques for both the diagnosis of and treatment of the disease. Smart apparel, smart phones and applications, and telemedicine are emerging as wearable tool that can continuously monitor the bone health and to give focused treatment plan. These technologies provide timely information to the physicians, and hence osteoporosis can be controlled effectively. <\/p>\n
Moreover, through Machine Learning interfaces used in diagnosis and prognosis of illness, medical images are used in predicting fracture risk resulting to early correct detection. It is expected to create new opportunities especially for the providers of the healthcare services and the patients involved in such services as well.
\nExpanding Healthcare Access in Emerging Markets<\/p>\n
One clearly defined unmet need in the postmenopausal osteoporosis market includes the introduction of health care access in developing countries where osteoporosis prevalence, as well as treatment, is still uncommon. Due to the increase in urbanization and better health care facilities and improving disposable income levels in emerging markets like China, India and Brazil future demand for better osteoporosis treatment is on the rise. Meanwhile, growth of these markets represents substantial opportunities to expand market penetration for osteoporosis drugs, diagnostics, and preventive therapies. <\/p>\n
This also gives the pharmaceutical companies the chance to introduce affordable products to respond specifically adequately to these regions, and subsequently open a new market to supply better medical needs for postmenopausal women.
\nPostmenopausal Osteoporosis Market Segment Analysis:
\nPostmenopausal Osteoporosis Market Segmented on the basis of Drug Class, Treatment Type, Route of Administration and Region.
\nBy Drug Class, Bisphosphonates segment is expected to dominate the market during the forecast period<\/p>\n
Bisphosphonates are widely used for postmenopausal osteoporosis because of their ability to decrease the activity of osteoclasts responsible for the bone solubilization. In bisphosphonates they inhibit the process of bone breakdown and this would lead to increased density and decrease in fracture rates. Some of the common BPs employed in treating patients with postmenopausal osteoporosis include; alendronate, risedronate, and zoledronic acid. These drugs comes in tablet form and in solution, which means that patients get to have some choice in how the drugs are administered.<\/p>\n
Monoclonal Antibodies are a relatively recent generation of drugs which are likely to find a rapidly growing role in osteoporosis therapy. Denosumab a monoclonal antibody with a broad receptor recognition profile acts by RANKL or receptor activator of Nuclear Factor Kappa B Ligand responsible for osteoclasts formation. Denosumab decreases the resorption of bone by osteoclasts and as a result strengthens the bone and thereby reduces fracture rate in postmenopausal women. Hormone Replacement Therapy (HRT) while not as often prescribed as in the past because of the risks of treatment, remains an ideal treatment regimen for any woman who needs estrogen to avoid bone loss. PTH analogues, including the drug teriparatide, are anabolic and are utilized in the management of severe osteoporosis exclusively. Last of all, There are Other drugs: SERMs, calcitonin, newer biologics of postmenopausal osteoporosis completes the medical management strategy.
\nBy Treatment Type, Drug Therapy segment expected to held the largest share <\/p>\n
Pharmacologic therapy is the mainstay of treatment of postmenopausal osteoporosis and multiple agents are aimed at decreasing bone resorption or at anabolic stimulation of bone formation. The key categories of the drugs are bisphosphonates, monoclonal antibodies, hormone replacement therapy, parathyroid hormone analogues, and selective estrogen receptor modulators. These drugs are taken either in tablets or in injections depending on the severity of the disease or osteoporosis, the health state of a patient and the presence of the concomitant illnesses. There is, therefore, an important and continuing reliance on drug therapy to prevent the occurrence of fractures, increase bone mineral density and decrease pain in osteoporosis.<\/p>\n
However, drug therapy is only part of the management of postmenopausal osteoporosis treatment, the other being Physical Therapy. There are elements by exercising that makes it useful in improving mobility, muscles strength and bone strength through exercises regimens. Lack of mobility exercises, balance exercises with body weights and resistance training are other key components of the physical therapy that builds up the bone strength and decrease the fractures rate. These exercises also enable the patient to control symptoms for example, pain and stiffness and therefore improving the patient\u2019s quality of life. Surgical treatment is occasionally required if complications such as fractures have developed Although much less common than conservative treatment methods, this method is a criterion for the last resort. Some measures include use of vertebral augmentation (vertebroplasty or kyphoplasty) for the purpose of securing newly broken vertebrate other surgical interventions like, arthritis of the hip, spinal stenosis, and fusion for deformities through osteoporotic breaks.
\nPostmenopausal Osteoporosis Market Regional Insights:
\nNorth America is Expected to Dominate the Market Over the Forecast period <\/p>\n
In 2023, North America will likely be the market leader in the postmenopausal osteoporosis market with a market share of about 40-45%. Such prevalence may be explained by the increase in age, a high level of expenditure on healthcare, and access to sophisticated treatments and diagnostics in this area. Currently, the U.S. forms a large part of this market share due to extensive use of osteoporosis drugs, routine bone health check-ups, and numerous awareness creation exercises. <\/p>\n
Canada also becomes one of the strategic countries that affect the growth in this region besides the United States. On the other hand, the Europe & Asia pacific regions are projected to register higher growth rates due to increasing proportion of elderly people and better health care systems respectively.
\nActive Key Players in the Postmenopausal Osteoporosis Market:<\/p>\n
Amgen (USA)<\/p>\n
Allergan (Ireland)<\/p>\n
Eli Lilly and Company (USA)<\/p>\n
GlaxoSmithKline (UK)<\/p>\n
Hoffmann-La Roche (Switzerland)<\/p>\n
Merck & Co. (USA)<\/p>\n
Mylan N.V. (USA)<\/p>\n
Novartis AG (Switzerland)<\/p>\n
Novo Nordisk (Denmark)<\/p>\n
Pfizer Inc. (USA)<\/p>\n
ProStrakan Group (UK)<\/p>\n
Sanofi S.A. (France)<\/p>\n
Servier Laboratories (France)<\/p>\n
Teva Pharmaceutical Industries Ltd. (Israel)<\/p>\n
UCB Pharma (Belgium), and Other Active Players.
\nKey Industry Development in the Postmenopausal Osteoporosis Market:
\nIn May 2023, Amgen announced real-world study results showing Prolia significantly reduced fracture risk in patients with postmenopausal osteoporosis. The data reinforced Prolia\u2019s efficacy in lowering the likelihood of fractures, supporting its role as a trusted treatment option. This study further demonstrated Amgen\u2019s commitment to addressing bone health challenges effectively.<\/p>\n","protected":false},"excerpt":{"rendered":"
Postmenopausal osteoporosis encompasses a situation where bones become fragile after the completion of menstruation in a woman which exposes the patient to frequent bone fractures.<\/p>\n","protected":false},"featured_media":23028,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-25837","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n